Table 5.
Analysis of the percentage reduction of the mean relative tumor area in the treated subgroups in comparison to the control group
| Threshold value |
Number of cases, n (%) |
|||
| k vs FOLFOXIRI | k vs GEMOX | k vs Gem/nab-P | k vs Gemcitabine | |
| -10% | 13 (87) | 13 (87) | 12 (80) | 13 (87) |
| -20% | 12 (80) | 10 (67) | 11 (73) | 11 (73) |
| -30% | 11 (73) | 8 (53) | 9 (60) | 8 (53) |
| -40% | 10 (67) | 6 (40) | 7 (47) | 7 (47) |
| -50% | 7 (47) | 5 (33) | 4 (27) | 4 (27) |
| -60% | 5 (33) | 1 (7) | 4 (27) | 1 (7) |
| -70% | 1 (7) | 1 (7) | 1 (7) | 0 (0) |
| -80% | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
k: Control group; GEM: Gemcitabine; GEMOX: Gemcitabine + Oxaliplatin; GEM/nab-P: Gemcitabine + nab-Paclitaxel; FOLFOXIRI: 5-Fluorouracil + Folinic acid + Oxaliplatin + Irinotecan.